The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
A treatment to reverse Alzheimer's Disease could be available in five years, it has been revealed. Experiments on mice have indicated that a new vaccine not only halts the advance of the disease ...